BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for iPS cells

Century Therapeutics Launches With $250 Million for Allogeneic iPSC Platform

By

  • Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies

  • Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatments

July 01, 2019, LEVERKUSEN, Germany & PHILADELPHIA & TOKYO–Century Therapeutics, which was created by Versant Ventures as part of the firm’s core strategy to launch innovative biotech companies, emerged from stealth mode today with USD 250 million in financing commitments from Bayer, Versant and Fujifilm Cellular Dynamics Inc. (FCDI). The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies. [Read more…]

Development of iPSC-derived Disease Models

By

Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment[3]. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]

Celgene to Pay Evotec $9 Million as Companies Expand iPSC Collaboration

By

Hamburg, Germany, June 5, 2019 — Evotec SE announced that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $9.0 m to Evotec.

Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Since then, the companies have achieved several milestones including advancement of one programme into lead optimisation as well as including additional cell lines and now a new cell type. [Read more…]

Takara Bio Establishes Foothold in the Pluripotent Stem Cell Market

By

Takara Bio EuropeTakara Bio broke news that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation of drug and medical products, granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells will be produced at Takara Bio’s manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe’s facility.

The announcement caught my attention, because to the best of my knowledge, Takara Bio is the first company worldwide to offer this service for human ESCs.

Takara Bio’s Role with Human Pluripotent Stem Cells

The significance of this event is that Takara Bio is now capable of providing a safe, reliable source of hES cells for future cellular therapeutic development by sourcing starting material from FDA-compliant facilities according to FDA guidelines and leveraging its proprietary, feeder-free hES cell establishment method, which is animal- and human-component free. [Read more…]

iPS Cell Market Poised for Burgeoning Growth

By

Recent years have seen major advances in the clinical applications of iPSCs, with Cynata Therapeutics progressing the world’s first formal trial of an iPSC-derived cell therapeutic and demonstrating that CYP-001, its lead iPSC-derived mesenchymal stem cell (MSC) product candidate, met all safety and efficacy endpoints in its Phase 1 trial for GvHD.

With multiple physician-led iPSC studies also underway in Japan for applications ranging from Parkinson’s disease to heart disease, the iPSC market is poised to for burgeoning growth. There has also been dramatic progress with production and differentiation technologies related to iPSCs, as well as growing use of iPSCs within drug discovery, disease modelling, tissue engineering, and precision medicine. [Read more…]

BioInformant's World-Class Clients